Why AdaptImmune collected $27.5M from GSK By: Philadelphia Business Journal via Business Journals July 24, 2018 at 12:20 PM EDT The two companies formed a partnership in 2014 to jointly develop T-cell therapies to treat cancer. Read More >> Related Stocks: Gsk Plc ADR